Concepedia

Karen C. Holdridge

KC

Statistics

Publications

21

Citations

1.8K

H-Index

17

Active since

2007

Affiliations

Eli Lilly (United States)(Current)

University of Southern California

Brigham and Women's Hospital

Massachusetts General Hospital

Indiana University – Purdue University Indianapolis

Karen C. Holdridge is an author at Eli Lilly (United States) specializing in dementia, medicine, and neurology.

Publications per year

2007–2025

21

Publications

21

Trial of Solanezumab in Preclinical Alzheimer’s Disease

Reisa A. Sperling, Michael Donohue, Rema Raman et al. · New England Journal of Medicine · 2023 · 379 citations · Full text

Medicine, Neurology, Pharmacology +17

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Stephen Salloway, Martin R. Farlow, Eric McDade et al. · Nature Medicine · 2021 · 365 citations · Full text

Medicine, Neurology, Pharmacotherapy +12

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals

Reisa A. Sperling, Michael Donohue, Rema Raman et al. · JAMA Neurology · 2020 · 329 citations · Full text

Medicine, Geriatric Medicine, Neurology +17

Seizure risk in patients with attention‐deficit‐hyperactivity disorder treated with atomoxetine

Joachim Wernicke, Karen C. Holdridge, Ling Jin et al. · Developmental Medicine & Child Neurology · 2007 · 89 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies

Reisa A. Sperling, Michael Donohue, Robert A. Rissman et al. · The Journal of Prevention of Alzheimer s Disease · 2024 · 87 citations · Full text

Medicine, Neurology, Neuroscience +17

1–5 of 21